Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) today announced that members of its management team will participate in two investor conferences in August and September 2026. President and Chief Executive Officer Dr. Seth Lederman will take part in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Aug. 11 from 1:30 p.m. to 1:55 p.m. ET. The company also said Lederman will participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Sept. 16. These events provide Tonix with an opportunity to discuss its business and engage with the investment community.
The company's participation in these conferences comes at a pivotal time as it seeks to build momentum following the approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years. Tonix is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra.
Beyond its commercial portfolio, Tonix is advancing a robust pipeline. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, the CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The investor conferences will allow Tonix to highlight these developments and its strategic direction to a broader financial audience. The company's presence at these events underscores its active engagement with the investment community and its commitment to transparent communication. Investors and industry observers will be keen to hear updates on the commercial rollout of TONMYA and progress across the pipeline.
For more information about Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP.
